Cargando…

TRK Inhibition with Entrectinib in Metastatic Salivary Secretory Carcinoma (SC): A Case Report

NTRK gene fusions are rare oncogenic driver mutations that can be found in a broad range of neoplasms. In secretory carcinoma (SC), ETV6-NTRK3 gene fusion is seen in a majority of the cases and represents a druggable target for patients with advanced disease in the absence of a currently accepted st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ernst, Matthew S., Lysack, John T., Hyrcza, Martin D., Chandarana, Shamir P., Hao, Desiree
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222047/ https://www.ncbi.nlm.nih.gov/pubmed/35735423 http://dx.doi.org/10.3390/curroncol29060314

Ejemplares similares

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
por: Pacenta, Holly L, et al.
Publicado: (2018)

Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion
por: Dunn, Danielle B.
Publicado: (2020)

The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer
por: Roth, Joshua A., et al.
Publicado: (2020)

Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers
por: Garcia-Foncillas, Jesus, et al.
Publicado: (2022)

A RESPONSE TO “THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER”
por: Ogale, Sarika, et al.
Publicado: (2020)

Clinicopathological investigation of secretory carcinoma cases including a successful treatment outcome using entrectinib for high-grade transformation: a case report
por: Suzuki, Kensuke, et al.
Publicado: (2022)

Mammary analogue secretory carcinoma of the salivary glands
por: Avondet, Lucas, et al.
Publicado: (2023)

Secretory carcinoma of major and minor salivary glands with ETV6-NTRK3 gene fusion: overcoming misdiagnosis in the era of tumour-agnostic therapy with TRK inhibitors
por: Durzyńska, Monika, et al.
Publicado: (2023)

Impact of neuroradiologist second opinion on staging and management of head and neck cancer
por: Lysack, John T, et al.
Publicado: (2013)

Mammary analogue secretory carcinoma in minor salivary gland
por: Ponso, Lucas Moreno, et al.
Publicado: (2022)

Entrectinib-Induced Heart Failure in a Patient With Metastatic Lung Adenocarcinoma: A Case Report
por: Otsu, Yukiko, et al.
Publicado: (2022)

Entrectinib-induced Brugada phenocopy in a patient with metastatic non-small cell lung cancer
por: Kubota, Megumi, et al.
Publicado: (2023)

Development of Neuropathic Arthropathy With Entrectinib: Case Report
por: Giustini, Nicholas P., et al.
Publicado: (2022)

Entrectinib for NTRK Fusion-Positive Metastatic Melanoma Progressing on Combined PD-1 and CTLA-4 Inhibition: A Case Report
por: Dawood, Shaheenah, et al.
Publicado: (2023)

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
por: Drilon, A., et al.
Publicado: (2016)

Finding and Characterizing Mammary Analogue Secretory Carcinoma of the Salivary Gland
por: Jung, Min Jung, et al.
Publicado: (2013)

Characterization of novel genetic alterations in salivary gland secretory carcinoma
por: Na, Kiyong, et al.
Publicado: (2019)

Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein
por: Fischer, Holger, et al.
Publicado: (2020)

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2015)

Entrectinib Induces Apoptosis and Inhibits the Epithelial–Mesenchymal Transition in Gastric Cancer with NTRK Overexpression
por: Sohn, Sung-Hwa, et al.
Publicado: (2021)

Two cases report of secretory carcinoma of the salivary gland in the lung: one primary and one metastatic after many years
por: Wang, Jing, et al.
Publicado: (2022)

Cytopathologic Features of Secretory Carcinoma of Salivary Gland: Report of Two Cases
por: Kim, Young Ah, et al.
Publicado: (2019)

Inhibition of planktonic growth and biofilm formation of Staphylococcus aureus by entrectinib through disrupting the cell membrane
por: Liu, Shanghong, et al.
Publicado: (2023)

Entrectinib for non-small cell lung cancer and solid tumours
Publicado: (2020)

Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations
por: Meneses-Lorente, Georgina, et al.
Publicado: (2023)

Proceedings of the North American Society of Head and Neck Pathology Companion Meeting, New Orleans, LA, March 12, 2023: Classification of Salivary Gland Tumors: Remaining Controversial Issues?
por: Skalova, Alena, et al.
Publicado: (2023)

Secretory carcinoma of the salivary gland, a rare entity: An international multi‐institutional study
por: Wiles, Austin B., et al.
Publicado: (2022)

Mammary Analogue Secretory Carcinoma (MASC) of salivary gland in four Mexican patients
por: Serrano-Arévalo, Mónica L., et al.
Publicado: (2015)

Clinicopathological characteristics and outcomes of 23 patients with secretory carcinoma of major salivary glands
por: Sun, Jingjing, et al.
Publicado: (2021)

Cytopathological Findings of Secretory Carcinoma of the Salivary Gland and the Diagnostic Utility of Giemsa Staining
por: Egusa, Yuria, et al.
Publicado: (2021)

Secretory breast carcinoma with metastatic sentinel lymph node
por: Vieni, Salvatore, et al.
Publicado: (2006)

An Unusual Salivary Gland Tumor Mimicking Papillary Thyroid Carcinoma: Mammary Analog Secretory Carcinoma
por: Asa, Sylvia L., et al.
Publicado: (2018)

Trk-fused gene (TFG) regulates pancreatic β cell mass and insulin secretory activity
por: Yamamotoya, Takeshi, et al.
Publicado: (2017)

Secondary Neuroendocrine Carcinoma Following High-Dose Radiotherapy for Head and Neck Cancer: Report of Two Cases
por: Taggar, Amandeep S, et al.
Publicado: (2016)

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
por: Drilon, Alexander, et al.
Publicado: (2022)

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
por: Amatu, Alessio, et al.
Publicado: (2015)

Response to Entrectinib in Differentiated Thyroid Cancer With a ROS1 Fusion
por: Liu, Stephen V., et al.
Publicado: (2017)

Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
por: Frampton, James E.
Publicado: (2021)

Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report
por: Damásio, Inês, et al.
Publicado: (2022)

Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib
por: Lazzari, Chiara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nem5ahs4l0k9f8jrssoeij6dad